Memantine Hydrochloride Tablet, Film Coated
Product Images NDC 0832-1112

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Memantine Hydrochloride (NDC 0832-1112). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Upsher-smith Laboratories, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Memantine 01)

Chemical structure diagram of Memantine Hydrochloride, showing a bicyclic amine structure with HCl and methyl groups attached.*

FDA Label Image

Figure 1 (Memantine 02)

A line graph comparing mean change from baseline in ADCS-ADL scores over 28 weeks of treatment for Memantine Hydrochloride and placebo groups. The x-axis represents weeks of treatment, and the y-axis shows mean change with error bars. The graph indicates clinical improvement and decline thresholds with horizontal dashed lines.*

FDA Label Image

Figure 2 (Memantine 03)

A line graph comparing the cumulative percentage of patients versus ADCS-ADL change from baseline for two groups: placebo and memantine. The graph shows two curves, with memantine consistently achieving higher cumulative percentages at greater negative ADCS-ADL changes, indicating treatment effects over baseline.*

FDA Label Image

Figure 3 (Memantine 04)

A line graph comparing mean change from baseline in SIB score over 28 weeks of treatment between Memantine and placebo groups. The x-axis represents weeks of treatment (0 to 28), and the y-axis shows mean change from baseline in SIB score ranging from -12 to 4. The Memantine group shows less decline and moves toward clinical improvement, while the placebo group shows greater clinical decline.*

FDA Label Image

Figure 4 (Memantine 05)

A cumulative percentage of patients line graph comparing SIB (Severe Impairment Battery) change from baseline for Memantine versus Placebo. The horizontal axis shows SIB change from baseline with negative values indicating improvement, while the vertical axis displays the cumulative percentage of patients. The chart features two curves, one for Placebo represented by squares and another for Memantine by circles, illustrating differences in treatment response over the range of SIB changes.*

FDA Label Image

Figure 5 (Memantine 06)

A line graph depicting change from baseline in ADCS-ADL scores over 24 weeks of treatment, comparing Placebo/Donepezil and Memantine/Donepezil groups. The x-axis shows weeks of treatment, and the y-axis shows mean change scores with clinical improvement and decline indicated. Error bars are present for each data point.*

FDA Label Image

Figure 6 (Memantine 07)

A cumulative percentage of patients chart comparing ADCS-ADL change from baseline between Placebo/Donepezil and Memantine/Donepezil groups. The x-axis represents ADCS-ADL change from baseline, ranging from 15 to -25, while the y-axis shows the cumulative percentage of patients from 0 to 100%. Two distinct lines track patient response distributions for each treatment group.*

FDA Label Image

Figure 7 (Memantine 08)

A line graph showing mean change from baseline in SIB score over 24 weeks of treatment, comparing Placebo/Donepezil and Memantine/Donepezil groups. The y-axis ranges from clinical decline to clinical improvement, illustrating the treatment effect over time with error bars.*

FDA Label Image

Figure 8 (Memantine 09)

A cumulative percentage plot showing patient response over SIB (Severe Impairment Battery) change from baseline values. Two treatment groups are compared: Placebo/Donepezil and Memantine/Donepezil, with the x-axis representing SIB change from baseline and the y-axis representing cumulative percentage of patients. The graph indicates higher cumulative percentage improvement with Memantine/Donepezil compared to Placebo/Donepezil.*

FDA Label Image

Principal Display Panel (5 mg Tablet Bottle Label)

Label for Memantine Hydrochloride Tablets, 5 mg, oral film-coated tablets. The package contains 60 tablets and is labeled for prescription use only. The label includes storage instructions and manufacturer information for Upsher-Smith Laboratories, LLC.*

FDA Label Image

Principal Display Panel (10 mg Tablet Bottle Label)

Memantine Hydrochloride Tablets 10 mg film-coated tablets label from Upsher-Smith Laboratories, LLC. The package contains 60 tablets with dosage information and storage instructions. The label includes NDC 0832-1113-60, barcode, and manufacturer details.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.